Showing posts with label cirm blog. Show all posts
Showing posts with label cirm blog. Show all posts

Wednesday, January 06, 2016

The Stem Cellar Named the World's Best Stem Cell Blog: Compelling Content, Commentary and More

The blog of the $3 billion California stem cell agency last month was ranked as the best stem cell blog in the world by the only entity that measures such things. 

The designation came from The Niche, a stem cell blog published by UC Davis researcher Paul Knoepfler, who on Dec. 22 identified the best blogs in the field for 2015. He said,

“The (top) prize goes to CIRM’s The Stem Cellar. While this is a tough choice (see more below on other stem cell blogs), CIRM’s blog has continued from year to year to step up its game. They post very often, sometimes daily. Their posts are composed of compelling content that includes reports on papers and other developments, but also commentary. I really appreciate the latter and that is fairly unique. They have also gone well beyond just focusing on CIRM-related matters to include broader issues for the stem cell field.”

(CIRM is the acronym for the California Institute for Regenerative Medicine, the formal name of the agency.)

Knoepfler continued,

“...(F)inishing a close second was Alexey Bersenev’s blog StemCellAssays. It continues to be incredible. Alexey regularly posts on the more technical side of stem cells, regenerative medicine, cellular medicine, and more. StemCellAssays is a much read for those interested in this field from any number of angles."

Kevin McCormack, WAF photo
The California Stem Cell Report, which was on Knoepfler’s short list, asked the stem cell agency about its blog, its readership and how it operates. Kevin McCormack, senior director of communications, replied,

“It was very flattering obviously to learn that Paul had named us as the #1 stem cell blog. We’ve been working hard to make our blog as engaging and thoughtful, and fun, as possible and this was vindication that at least in his eyes we had succeeded.

“Our strategy is really quite simple. We look for what we think are the best, most interesting stories out there, and then write about them. Obviously we like to highlight stories about research we are funding but more often than not we’re just looking for something new, something fresh, something that sheds a new light on research in general or on tackling a particular disease or problem in particular.”

(For the full text of McCormack’s reply, see here.)

Todd Dubnicoff, CIRM photo
Karen Ring, CIRM photo
In addition to McCormack, three other CIRM team members write for The Stem Cellar, which posts virtually five days a week. They are Karen Ring, a former stem cell researcher, Don Gibbons and Todd Dubnicoff. The pace of postings is important because it is generally believed in the blogosphere that blogs must be fed often to keep readers interested.


Don Gibbons, CIRM photo
The activity on the blog has additional significance since CIRM’s home page is fundamentally static and rarely changes on a day-to-day basis. So the liveliness on the blog helps keep people coming back to the agency’s information where it touts its success. 

As for readership of the blog, it obviously draws attention from scientists and patients. But the audience is small compared to the mammoth numbers chalked up by big name blogs, which count their readership in millions. McCormack said WordPress reported 127,995 page views for 2015 for the agency’s blog. (For more numbers, see here.).

A Pew Research Center study reported last year that the number of scientists who are blogging is growing as awareness increases about the importance of making full use of Internet communications tools.

Susan Gunelius, writing on the ACI Information Group's Web site, said,
"Certainly, the more scientists who publish blogs and share their findings via social media, the more the public will learn about science from reputable sources. With that in mind, let’s hope that the number of scientists who are active on social media and writing blogs continues to grow!"
Here is the list of the other stem cell blogs rated highly by Knoepfler: the California Stem Cell Report,  EuroStemCell, ISSCR Blog, msemporda, Signals Blog, Stem Cell Assays, Stem Cell Podcast, Stem Cells Buzz, The Node.

Knoepfler, who has received grants from the California stem cell agency, reported that msemporda and Stem Cells Buzz are new to the game.

CIRM's Approach to Stem Cell Blogging: The Full Text

The California Stem Cell Report asked the California stem cell agency for a run down on how it approaches its blog, which in December was rated the top stem cell blog of 2015 by The Niche, another stem cell blog published by UC Davis researcher Paul Knoepfler.

Kevin McCormack, senior director for communications, replied,
"It was very flattering obviously to learn that Paul had named us as the #1 stem cell blog. We’ve been working hard to make our blog as engaging and thoughtful, and fun, as possible and this was vindication that at least in his eyes we had succeeded.

"Our is really quite simple. We look for what we think are the best, most interesting stories out there, and then write about them. Obviously we like to highlight stories about research we are funding but more often than not we’re just looking for something new, something fresh, something that sheds a new light on research in general or on tackling a particular disease or problem in particular.

"We try to divide it up so that we all write a blog every week, that way we get different voices and flavors in the mix. I think that’s important for a number of reasons. One, it creates a sense that this is truly a team blog, and two, it allows each of us to take a little bit more time in writing each piece, to make sure we get it right and to do it in a way that is most interesting and accessible for our audience.

"We have a really broad range of people reading us from researchers and scientists to people with no science background (like me), so we are always mindful of trying to write in a way that allows everyone to understand what’s going on. We also try to write in a way that reflects how exciting this research is and the potential it has. But we also try to balance that by reminding people that some of this work was done in animals and needs to be replicated in people before we get carried away.

"One of the new things that Dr. Karen Ring has added, since joining us this year, is more individual profiles of young researchers. These have been popular in helping give a voice to a group of people who are often overlooked, the youngest members of the research teams, the people who represent the future of stem cell research and are the next generation of scientific stars.

"We are always looking to add new ideas, new voices to the blog. So if you have any thoughts or ideas left over from your own, let us know. We’re happy to try anything. At least once."

Readership Numbers on the California Stem Cell Agency's Blog

The California Stem Cell Report asked the state stem cell agency for readership statistics on its blog, named in December as the best stem cell blog in the word. Here is the text of what Kevin McCormack, senior director for communications, sent along.

"We only have stats from May 2014 because that is the date when this blog was switched to Wordpress (that’s also the reason why the viewing figures for May were so low, it took people a while to find the new site). The blog started in 2007 on a site called blogspot.
"Data from 2015:
Home page views: 34,871
Top blog reads: 2,336
Best ever views: Sept 2nd 2015 with 1,454 views
"From May 2014-Dec 2015
Views went from 60  to ~13,000

Months and years





Average per Day
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Overall
2014
2
57
194
235
194
273
381
309
209
2015
356
309
335
251
301
345
268
323
441
440
446
429
353
"Referrers (in order of top views)
1)    Search Engines (google, bing, yahoo)
2)    Facebook
3)    Twitter
"Total # Posts: 1,555
"Total followers: 485 (115 on wordpress and 370 on email subscription)"

Friday, February 06, 2015

A California Stem Cell Plus: Cash Counts on Research Publications

“Money matters,” says the $3 billion California stem cell agency. And it is right.

The agency was commenting yesterday on a study published this week that indicated that the Golden State has “over-performed”in terms of publication of research findings as the result of the agency’s efforts.

The comment appeared on The Stem Cellar, the agency’s blog. Kevin McCormack, senior director of communications, wrote,
“The question the researchers posed was; have the states that fund stem cell research seen an increase in their share of scientific publications in the field? The answer, at least in California’s case, is absolutely yes.” 
The study by Aaron Levine of Georgia Tech said its findings “suggested” that the increase was due to 667 awards totaling $1.9 billion made by the stem cell agency over the last 10 years.

As Levine’s article noted, many other factors need to be examined to determine whether the agency has met the goals of the 2004 ballot campaign that created the stem cell research effort. But for now, the piece by Levine is a significant plus for the California Institute for Regenerative (CIRM), as the agency is formally known. And it comes from an independent source, one that is not financed by the agency, as some other studies have been.

Saturday, January 31, 2015

The Stem Cellar: California Stem Cell Agency on Gordie Howe and Human Tissue Donations

The Stem Cellar is the blog of the California stem cell agency, and it is consistently worthy of attention.

For the most part it deals with scientific issues, only occasionally touching on other matters. Of course, it does serve as a vehicle for selling the agency’s programs and informing readers about their benefits.

On Friday, the Stem Cellar dealt once again with the Gordie Howe stem cell treatment situation, which received a fair amount of attention over the holidays in December.

The case involved a San Diego firm and treatment of the famed hockey star in Tijuana. Most of the coverage in the mainstream media has largely accepted the claims that the treatment has been wildly successful.  

Don Gibbons, senior science and education officer, wrote on Friday, 
“Finally some healthy skepticism has arrived. Hockey legend Gordie Howe’s recovery from a pair of strokes just before the holidays was treated by the general media as a true Christmas miracle. The scientific press tried to layer the coverage with some questions of what we don’t know about his case but not the mainstream media. The one exception I saw was Brad Fikes in the San Diego Union Tribune who had to rely on a couple of scientists who were openly speaking out at the time. We wrote about their concerns then as well.
"Now two major outlets have raised questions in long pieces back-to-back yesterday and this morning. The Star in hockey-crazed Canada wrote the first piece and New York Magazine wrote today’s. Both raise serious questions about whether stem cells could have been the cause of Howe’s recovery and are valuable additions to the coverage."
Gibbons also wrote on another subject.
“A University of Michigan study suggests most folks don’t care how you use body tissue they donate for research if you ask them about research generically. But their attitudes change when you ask about specific research, with positive responses increasing for only one type of research: stem cell research.
“On the generic question, 69 percent said go for it, but when you mentioned the possibility of abortion research more than half said no and if told the cells might lead to commercial products 45 percent said nix. The team published their work in the Journal of the American Medical Association and HealthCanal picked up the university’s press release that quoted the lead researcher, Tom Tomlinson, on why paying attention to donor preference is so critical:
“'Biobanks are becoming more and more important to health research, so it’s important to understand these concerns and how transparent these facilities need to be in the research they support.'
“CIRM has begun building a bank of iPS-type stem cells made from tissue donated by people with one of 11 diseases. We went through a very detailed process to develop uniform informed consent forms to make sure the donors for our cell bank knew exactly how their cells could be used. Read more about the consent process here.” 
We should also note that The Stem Cellar is several notches above what the agency used to produce several years ago for a blog. It is informative, explanatory and accessible and improving.

(Editor's note: An earlier version attributed The Stem Cellar item to Anne Holden based on incorrect information on the CIRM blog that indicated that she had written the piece.) 

Monday, November 19, 2012

California Stem Cell Agency Blogs on Geron Clinical Trial

The California stem cell agency published an article online last week concerning the hESC clinical trial that Geron abandoned last year, dealing mainly with one of the participants in the program.

The piece was studiously non-committal about whether the $3 billion research program is likely to fund the trial once again, should BioTime, Inc., of Alameda, Ca., be successful in acquiring the assets of once was the first hESC clinical trial in the United States. The agency loaned Geron $25 million a few months before the company cancelled the trial.

Amy Adams, CIRM's communications manager, simply wrote,
“They (BioTime) would need to apply for a loan if they want CIRM to financially support the continued trial.”
The latest round of funding that BioTime could apply for has a deadline of Dec. 18 for letters of intent. In addition to a loan, a grant is also a possibility.

Adams focused on Katie Sharify, who was enrolled in the clinical trial shortly before Geron said it was dropping the effort for financial reasons. Adams interviewed Sharify before an audience of scientists.

Adams wrote,
“Katie told me that it would be impossible not to hope that a trial would help her, but that by the time she made the decision to participate she knew she was doing it to further science, not necessarily to further her own recovery. She told the audience, 'I was part of something that was bigger than me, and bigger than all of you.'”
Stem cell scientist Paul Knoepfler of UC Davis also wrote about the BioTime-Geron deal last week. Noting that Geron's decision a year ago left many “upset to put it mildly,” Knoepfler said the “idea of BioTime buying the Geron stem cell program is a great one that provides new hope on many levels.”


Search This Blog